INTRODUCTION {#sec1-1}
============

The number of children undergoing complex surgeries for congenital heart diseases is increasing day by day. In comparison to adults, children are at an increased risk of postoperative bleeding. The amount of blood loss and transfusion in children undergoing cardiac surgery is up to 15--110 and 155 ml/kg, respectively.\[[@ref1][@ref2]\] A study by Chambers *et al*. in 1996 documented that 98% of children who underwent cardiac surgery (with the aid of cardiopulmonary bypass \[CPB\]) received packed red blood cells (RBCs).\[[@ref3]\] A recent review reported that 38--74% of children who underwent cardiac surgery received a blood transfusion.\[[@ref4]\]

RISKS AND CLINICAL IMPACT OF BLOOD TRANSFUSION {#sec1-2}
==============================================

The most common complications of blood transfusion are leukocyte-related target organ damage (2--5%), febrile nonhemolytic transfusion reaction (1%), transfusion-related lung injury (0.05%), and bacterial infection (0.05%).\[[@ref5]\] Blood transfusion leads to increased incidence of infections (sepsis), respiratory complications (acute lung injury), cardiac complications (low cardiac output syndrome, increased inotropic usage), renal complications (acute kidney injury), duration of mechanical ventilation, Intensive Care Unit (ICU) and hospital length of stay, and cost of treatment and mortality.\[[@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12]\] In pediatric patients undergoing heart transplant increasing amount of RBC transfusions are associated with increase length of ICU stay, inotropic scores, and major adverse events. Following modified Blalock--Taussig shunt procedures, blood transfusion \>6 ml/kg is an independent risk factor for mortality.\[[@ref13]\] Larger volume blood transfusion correlates with longer intubation durations, ICU and hospital stays, higher peak C-reactive protein levels, and an increased blood urea nitrogen/creatinine ratio.\[[@ref14]\] Increased volume of packed blood cells when used in CPB prime and during CPB lead to excessive postoperative bleeding in pediatric cardiac surgery.\[[@ref15]\]

CHALLENGES FOR BLOOD CONSERVATION IN PEDIATRIC AGE GROUP {#sec1-3}
========================================================

Children pose a unique set of challenges pertaining to blood conservation due to their small blood volume; large priming volume of CPB circuits, requirements of higher hematocrit during CPB, presence of cyanosis in some children, immature coagulation system and hypothermia during CPB. Congenital deficiency of coagulation factor VII, VIII or von Willebrand factor further increases the risk of bleeding and therefore, blood transfusion.\[[@ref16][@ref17][@ref18]\] Furthemore, children with cardiac lesions involving systolic flow abnormalities are at increased risk of developing qualitative platelet dysfunction than those with diastolic flow abnormalities.\[[@ref19]\] The exposure to extracorporeal circuit also leads to the development of qualitative and quantitative platelet abnormalities, coagulation factor deficiencies, and hypofibrinogenemia.\[[@ref20]\]

STRATEGIES {#sec1-4}
==========

The strategies for conserving blood in children undergoing cardiac surgery are listed in [Table 1](#T1){ref-type="table"}.

###### 

Strategies for blood conservation in pediatric cardiac surgery

  ------------------------------------------------------
  Preoperative
   Autologous blood donation
   Erythropoietin therapy
  Intraoperative
   Monitoring lines and sampling volume
   Acute normovolemic hemodilution
   Anti-fibrinolytics
   Retrograde autologous priming
   Miniature circuits
   Microplegia
   Ultrafiltration
   Vacuum assisted venous drainage
   Surface modified bypass circuits
   Cell saving devices
   Special coagulators
   Topical hemostatic agents
  Postoperative
   Point of care tests and transfusion algorithms
   Antifibrinolytics and aprotinin
   Recombinant activated factor VII
   Reducing blood sampling in the postoperative period
  ------------------------------------------------------

Preoperative {#sec2-1}
------------

### Autologous blood donation {#sec3-1}

Autologous blood donation (ABD) is usually done in children more than 3 years of age or weight more than 15 kg. A femoral vein or an external jugular vein may be used for withdrawing blood under mild anesthesia. Repeated withdrawals are required, and a volume of 10 ml/kg may be collected per phlebotomy while replacing the volume and electrolyte deficit with 0.9% saline or colloid. Autologous blood may be stored for 3 weeks with a citrate phosphate dextrose adenine (CPDA) solution in liquid form and up to 6 weeks with cryopreservation. In smaller children, once maximum permissible blood is withdrawn a 3--4 week interval is required before another donation. The last donation may be as late as 1 week before surgery. The volume to be drawn to successfully avoid homologous blood transfusion can only be learned by experience.\[[@ref21]\] The demerits of ABD are that every autologous donation is succeeded by erythropoietin (EPO) therapy, practically cumbersome, difficult with poor venous access, increased the load on blood bank services, repeated visits are required, requires convincing the child, increased the cost of treatment, and complications of EPO therapy.

Komai *et al*. developed a protocol in which they withdrew 8 ml/kg of autologous blood twice before surgery and administered human EPO 100--300 units/kg subcutaneously at each donation. The blood was replaced with 16 ml/kg of the electrolyte solution, and the iron supplement was given after each EPO injection. For intraoperative blood conservation, they used aprotinin, ultrafiltration (conventional and modified), and infusion of residual CPB blood, after washing with an autotransfusion device.\[[@ref22]\]

### Erythropoietin therapy {#sec3-2}

EPO therapy in the preoperative period may be used in children with low preoperative hemoglobin or as a part of ABD. Recombinant human EPO (rHuEPO) is administered in a dose of 300 µ/kg 1 week before autologous donation or surgery. The same dose may be repeated at subsequent autologous donations. Supplemental iron, Vitamins (A, C, K), folic acid and B~12~ are also given at the time of rHuEPO. Hypertension and flu-like syndrome are common side effects of EPO therapy.\[[@ref23]\] Pretreatment with rHuEPO, 1 week before surgery, increases the hematocrit significantly in a dose-dependent manner. Anemic patients may benefit more than nonanemic ones. The decrease in the incidence of packed RBC (pRBC) transfusion in the postoperative period may not be significantly less.\[[@ref24]\]

Intraoperative {#sec2-2}
--------------

### Monitoring lines and sampling volume; closed blood conservation device {#sec3-3}

While acquiring invasive lines for monitoring certain precautions may help in avoiding excessive blood loss, especially in small neonates. Repeated attempts at same site should be avoided and in the case of failed puncture prompt compression of puncture sites should be done. Whenever feasible a change in the site for vascular access and possibly a change of hands are advisable. Limiting frequent flushing of invasive lines prevents hemodilution and whenever desirable the sampling volumes should be restricted to minimum (≤1 ml). Recent clinical analyzers may provide an arterial blood gas analysis with as little as three drops of blood. The use of "double stopcock technique" decreases hemodilution and conserves blood \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref25]\]

![Double stopcock technique](ACA-19-705-g001){#F1}

The use of a closed blood conservation device, the venous arterial blood management protection system, decreases the incidence of catheter-related contamination of the intraluminal fluid.\[[@ref26]\]

### Acute normovolemic hemodilution {#sec3-4}

There are no general guidelines for acute normovolemic hemodilution (ANH) before going on CPB. Before initiating ANH, it is prudent to have a hematocrit \>30% at baseline. The blood may be withdrawn using an arterial or a central venous line. Sufficient volume of blood that can be withdrawn without causing hemodynamic unstability cannot be predicted; however, a safe assumption may be to withdraw not more than 10--15% of blood volume while replacing the fluid deficit with either crystalloid or colloid. Furthermore, it is important to monitor perfusion and oxygenation of vital organs. Near infrared spectroscopy may be used to measure the cerebral oxygenation in addition to the routine American Society of Anesthesiologists monitoring.\[[@ref27]\] The withdrawn autologous blood is anti-coagulated with appropriate amount of CPDA solution or blood may also be withdrawn after heparin administration. It is not uncommon to transfuse the autologous blood during CPB to maintain the target hematocrit. While reinfusing the withdrawn blood calcium chloride (10 mg/kg) or gluconate is administered to counter the chelation of calcium ions by CPDA solution.\[[@ref28]\] The advantage of ANH is that diluted blood is lost during surgery and postoperatively fresh whole blood is transfused (which reduces postoperative bleeding the best).

### Anti-fibrinolytics {#sec3-5}

In the normal coagulation pathway, the formation of fibrin is followed by fibrinolysis mediated by plasmin. Alpha2 anti-plasmin inhibitor is a naturally occurring anti-fibrinolytic protein which regulates the fibrinolysis. It is a potent inhibitor of free plasmin but has only a mild effect on plasmin bound to fibrin. Aprotinin acts in a similar fashion and improves hemostasis. However, tranexamic acid and epsilon aminocaproic acid (EACA) prevent excessive plasmin formation by inhibiting binding of plasminogen with fibrin. They acquire the lysine binding site of plasminogen and prevent its interaction with fibrin.

**Aprotinin**

Aprotinin inhibits trypsin, chymotrypsin, plasmin, kallikrein, elastase, and thrombin. It decreases activation of the contact system, prevents fibrinolysis, and preserves platelet function. Aprotinin prevents proteolysis of the major thrombin receptor on platelets (PAR 1), thereby preventing platelet activation. Due to its anti-inflammatory effect, there is a decrease in the level of cytokines interleukin (IL)-6, IL-8, tumor necrosis factor-α, and expression of macrophage 1 antigen.

Aprotinin when introduced in clinical practice was accepted universally as a prophylactic and therapeutic hemostatic agent in the perioperative period.\[[@ref29][@ref30]\] The safety of aprotinin came into question when two studies -- Blood Conservation using Anti-fibrinolytics in a Randomized Trial and a study by Mangano *et al*. suggested that aprotinin increased the incidence of major adverse events and mortality. These observations were followed by withdrawal of aprotinin from the market. Later, the Food and Drug Administration (FDA) re-analyzed the data of all studies that concluded against aprotinin and found there were many confounding factors influencing the conclusion.\[[@ref31][@ref32][@ref33][@ref34]\] Thereafter, Health Canada licensed the use of aprotinin in revascularization surgeries. Aprotinin has been shown to reduce perioperative bleeding and blood transfusion during reoperations and congenital heart surgery.\[[@ref35]\]

**Tranexamic acid**

A 100 mg/kg bolus before skin incision and an intraoperative infusion of 10 mg/kg/h was effective in conserving blood and improved clinical outcomes after pediatric cardiac surgery.\[[@ref36]\] The optimal dose that can be recommended for prophylaxis against postoperative bleeding is not yet determined. However, it has been postulated that the adverse events after tranexamic acid administration may be dose-dependent.\[[@ref37]\]

Prospective studies to evaluate the safety profile and potential adverse effects in the pediatric cardiac population are also lacking. Therefore, the association of tranexamic acid with seizures is based on underpowered studies.

**Epsilon aminocaproic acid**

Following the withdrawal of aprotinin from the market, clinicians resorted to alternate anti-fibrinolytics, tranexamic acid, and EACA. The use of EACA in pediatric cardiac surgery was not recommended till now because of the lack of studies documenting its safety profile in children. Compared to placebo, EACA was associated with decreased postoperative blood loss, reduction in blood transfusion, reduction in re-exploration rate, higher platelet counts, lower activated clotting time (ACT), and higher fibrinogen levels in children undergoing cardiac surgery.\[[@ref38][@ref39][@ref40][@ref41][@ref42]\] A metaanalysis compared five studies and concluded "EACA should be recommended for the prevention of postoperative blood transfusion in pediatric cardiac surgery." The authors of the above-stated meta-analysis have cited several limitations of their study, but an additional limitation of their study was that four out of five studies they selected for analysis were from a single institute.\[[@ref43]\] Furthermore, these studies were not designed to study the safety profile of EACA administration in children; therefore, additional prospective studies specifically designed to study adverse effects of EACA are required before a recommendation may be made for its routine use in pediatric cardiac surgery.

Before recommending the alternative anti-fibrinolytics for routine prophylaxis, the safety profile needs to be adjudged so that they do not meet the fate of aprotinin.

### Retrograde autologous priming {#sec3-6}

Retrograde autologous priming (RAP) is done to either completely or partially replace the prime volume of the CPB pump. It takes about 4--5 min before commencing CPB. By displacing 50% of prime volume with RAP hematocrit is reduced by 50% only (vs. 75% without RAP). To counteract the transient fall in mean arterial pressure (MAP \<35 mm Hg infants) small boluses of phenylephrine (10 μg) may be used.

### Miniature circuits {#sec3-7}

Miniature circuits are modified and dwarfed versions of conventional CPB circuits (CCPBs). With different permutation -- combinations of the diameter and size of tubing, of the CPB circuit, prime volume can be varied between 110 and 170 ml for children \<5 kg. The internal diameter of the arterial line can be decreased to 1/8". The arterial filter has been eliminated from certain oxygenators which use "Self-venting technology" to get rid of air bubbles. Oxygenators such as Kids D100 (Sorin) and Baby FX (Terumo) decrease prime volume and prevent hemodilution. To decrease the length of venous tubing, the venous reservoir is elevated to the level of the right atrium and venous return is maintained using vacuum-assisted venous drainage (VVAD). Because of the decrease in prime volume, hemodilution is much less and there is no requirement of hemofilter. Examples of different combinations of microcircuits are - 1/8" A line + 3/16" V line + Baby RX 5/Lilliput 1 = 175 ml prime (No arterial filter) and 1/8" A line + 3/16" V line + Kids D 100 + Sorin arterial filter D 130 = 110 ml.

Kotani *et al*. combined different sizes of arterial (5/16"; 1/4"; 3/14") and venous (5/16"; 1/4") lines and compared different arterio-venous combinations with respect to amount of prime volume, blood transfusion, sodium bicarbonate use (to maintain pH), and hemodynamics. They concluded that downsizing the lines decreased prime volume, blood transfusion, and sodium bicarbonate use but had no effect on hemodynamics.\[[@ref44]\]

Miniature extracorporeal circuits (MECC) are half as long as CCPBs.\[[@ref45]\] MECC decrease the interactions between blood and artificial surface, therefore, preventing an exaggerated systemic inflammatory response during CPB.\[[@ref45]\] Mini-CPB requires one-third of blood transfusion compared to CCPB with lesser postoperative bleeding and blood transfusion-related complications.\[[@ref46][@ref47][@ref48]\]

MICROPLEGIA {#sec1-5}
===========

To deliver microplegia blood is diverted from the arterial line of the CPB circuit or a special port from oxygenator through a roller pump. The cardioplegia with high potassium content (40 or 100 mEq/l) is delivered in this blood by a syringe pump. A ratio of 1 part cardioplegia and sixty parts blood is achieved by maintaining the infusion rate of a roller pump in ml/min and that of the syringe pump in ml/h, while keeping the numeric value constant (e.g., 10 ml/min of roller pump = 10 ml/h of syringe pump). Microplegia prevents hemodilution, especially on repeated delivery, decreases the tendency for tissue edema, and provides better myocardial protection, higher oxygen delivery (higher hemoglobin), and negligible fluid balance of cardioplegia.\[[@ref49][@ref50][@ref51]\] The advantages of microplegia have not been studied exclusively in pediatric patients undergoing cardiac surgery.

A North American survey of 122 congenital heart surgeons revealed that 5% of them use microplegia, consisting of oxygenated blood with potassium concentration of 40 or 100 mEq/l during pediatric cardiac surgery.\[[@ref52]\] In this survey, the temperature at which Microplegia was used varied between \<5 and 20°C, induction dose between 10 and 30 ml/kg and maintenance dose between 5 and 10 ml/kg. The redosing interval has been debated and may vary from 15 to 35 min.\[[@ref53]\]

ULTRAFILTRATION {#sec1-6}
===============

Conventional ultrafiltration increases hematocrit and postoperative blood loss after pediatric cardiac surgery. It helps in eliminating inflammatory mediators generated during CPB. Children who are operated under profound hypothermia are the most benefited. In comparison with cell saving devices (CSDs) plasma proteins and platelets are preserved during ultrafiltration. In children undergoing cardiac surgery modified ultrafiltration (MUF) increases hematocrit, improves hemostasis, decreases blood loss and transfusion, and increases levels of prothrombin, factor VII and fibrinogen.\[[@ref5][@ref54][@ref55][@ref56][@ref57]\] A systematic review by Kuratani *et al*. highlighted that, compared to CUF, MUF increases post-CPB hematocrit significantly, but the decrease in chest tube drainage is not significant when compared with controls.\[[@ref58]\] Longer duration of MUF is associated with better hematocrit and blood pressure in infants undergoing arterial switch operation.\[[@ref59]\] A demerit of ultrafiltration is that cannot be used with miniaturized circuits.

VACUUM-ASSISTED VENOUS DRAINAGE {#sec1-7}
===============================

Earlier used as a troubleshooting therapy in patients with compromised venous drainage during CPB, VAVD is now an essential component of microcircuitry used in pediatric CPB. As discussed above, with microcircuits the hard shell reservoir is nearly at the level of the right atrium. Therefore, there is a loss of the siphoning effect of the gravity dependent drainage. VAVD compensates for this loss of gravity dependent drainage and allows the reservoir and rotor pump to be raise to the patient level.\[[@ref60]\] With VAVD the venous return may be increased by as much as 40% in 3/16 inch tubing. For example, 20 cm reservoir age/reservoir drainage height + 40 mm Hg vacuum to the reservoir is equivalent to a 72 cm drainage height.

Since the venous drainage is essentially dependent on vacuum suction, a backup should be available at all times to circumvent any failure of the vacuum device. It has been reported that there is an increased formation of gaseous microemboli with an increase in the vacuum level. A vacuum suction pressure of \<40 mm Hg is associated with the same embolic load as gravity dependent siphon drainage.\[[@ref61]\] Therefore, it is recommended not to increase the vacuum level more than 40 mm Hg. Hemolysis may also occur which can be prevented by decreasing hematocrit on CPB (25%) and avoiding high suction pressures. A safety feature in form a pressure relief valve is present on VAVD device which opens at + 5 mm Hg or −80 mm Hg.\[[@ref62]\]

SURFACE MODIFIED BYPASS CIRCUITS {#sec1-8}
================================

The use of an artificial circuit triggers an inflammatory response during CPB. To prevent this inflammatory response, various agents have been used to coat the surface of the CPB circuit. Heparin, trillium, poly-2-methoxyehylacrylate, phosphorylcholine, and senko e-ternal coating has been used till date.\[[@ref63][@ref64][@ref65][@ref66][@ref67][@ref68][@ref69][@ref70]\] The purpose of modifying the surface of extracorporeal circuit is to prevent the inflammatory response that occurs during CPB. Therefore, the majority of studies done on surface modified circuits have evaluated the rise and fall in the serum levels of inflammatory cytokines and molecules.\[[@ref63][@ref64][@ref65][@ref66][@ref67][@ref68][@ref69]\] These studies were not designed to study the effects of surface modifying agents on bleeding and blood transfusion after cardiac surgery. Hence, with the currently available literature, it cannot be established that surface modified CPB circuits decrease bleeding and postoperative blood transfusion.

CELL SAVING DEVICES {#sec1-9}
===================

CSDs were assumed to be of benefit in adult surgeries with huge amounts of blood loss because the volumes required to process in the earlier CSDs were large. With the development of newer continuous centrifugation CSD, which can process as little as 30 ml blood continuously, without delay, their role in pediatric cardiac surgery is increasing. A CSD not only conserves blood but also removes debris and therefore decreases the risk of embolism. The processing of blood in a cell saver removes coagulation factors, platelets, and plasma proteins and may cause bleeding due to residual anti-coagulant. Therefore, it is essential to reverse the residual heparin by protamine. Any residual blood post-CPB should be collected in a bag and transfused as and when required rather than subjecting it to a cell saver because it is safe, efficient, simple, and less expensive than CSD.

Cell saver blood can be safely stored at the bedside for 24 h after collection from neonates and infants undergoing cardiac surgery. The transfusion of this blood decreases the amount of RBC and blood products transfusion in the immediate postoperative period (48 h) significantly. However, within 7 days after surgery, the difference was not found to be statistically significant.\[[@ref71]\] From an economic point of view, cell salvage and allogenic blood transfusion are least expensive, followed by cell salvage and autologous blood transfusion, allogenic blood transfusion alone and autologous blood transfusion alone.\[[@ref72]\]

SPECIAL COAGULATORS {#sec1-10}
===================

Ultraincision harmonic scalpel cuts and coagulates at the same time. The vibration (55,500 Hz) of the scalpel cuts through tissue, and the protein denaturation seals it. Initially developed with the intention of improving surgical dissection and reducing tissue trauma, it was found to improve hemostasis during operations. A study of 150 adult patients undergoing redo surgeries found that the use of harmonic scalpel decreased mediastinal chest tube drainage, allogenic blood transfusion and the transfusion of fresh frozen plasma in the postoperative period. The use of harmonic scalpel was associated with better postoperative outcomes.\[[@ref73]\] However, similar studies in the pediatric age group are lacking. One case of the surgical division of a double aortic arch in a 2.0 kg child using harmonic scalpel has been reported.\[[@ref74]\]

TOPICAL HEMOSTATIC AGENTS {#sec1-11}
=========================

There are different types of topical hemostatic agents available for use in patients undergoing cardiac surgery:\[[@ref75]\]

Fibrin sealant - TISSEEL, Beriplast P, VivostatAbsorbable gelatin sponge - SpongostanOxidized regenerated cellulose - SurgicalGelatin and thrombin - FlosealMicroporous polysaccharide - HemoStaseChitin and chitosan based agents - HemCon; Chitoseal.

The literature regarding the use of topical hemostatic agents in pediatric cardiac surgery and their effect on postoperative bleeding and blood transfusion is very less. The only randomized controlled trial in pediatric cardiac surgery evaluating the use of a fibrin sealant was published by Codispoti and Mankad in 2002. The authors of this study concluded that the use of a fibrin sealant, intraoperatively, decreased bleeding, blood transfusion, and the time for surgical hemostasis.\[[@ref76]\] Huth *et al*. studied fibrin sealant in children with tetralogy of Fallot and transposition of the great arteries, retrospectively, and concluded that use of tisseel decreased immediate postoperative blood loss.\[[@ref77]\]

Other studies had enrolled mixed population or only adults in comparing different hemostatic agents either among themselves or controls. The results of all these trials and a systematic review by Rousou *et al*. have established the efficacy of topical agents as effective modalities to conserve blood.\[[@ref78][@ref79][@ref80][@ref81][@ref82][@ref83]\]

Postoperative {#sec2-3}
-------------

Point of care (POC) tests and transfusion algorithms (transfusion trigger)Anti-fibrinolytics and aprotininRecombinant activated factor VII (rFVIIa)Reducing blood sampling in the postoperative period.

### Point of care tests and transfusion algorithms {#sec3-8}

In pediatric cardiac surgery, there is a significant dilution of coagulation factors when the half of the total blood volume is replaced by fluids, which are deficient in coagulation factors (pRBCs, crystalloids, or colloids).\[[@ref84]\] In small children, there is a more than 50% decrease in coagulation factors at the initiation of CPB.\[[@ref85]\] The fibrinogen level may fall below 1 g/dl in neonates after CPB.\[[@ref86]\] The incidence of various abnormalities post-CPB are -- thrombocytopenia (\<100,000/mm^3^) - 60%, qualitative platelet defects 10--33%, coagulation factor deficiency (\<20% activity) - 30% and hypofibrinogenemia (\<100mg/dl) - 9%.\[[@ref20]\] The following POC tests may help to identify the above defects in the ICU.

ACTPlatelet countFibrinogen levelsProthrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratioViscoelastic tests: Thromboelastography (TEG), Sonoclot, rotational thromboelastometry (ROTEM)Qualitative platelet function tests.

**Viscoelastic tests**

Thromboelastography can predict postoperative bleeding, after heparin neutralization, in both cyanotic and acyanotic children undergoing cardiac surgery.\[[@ref87][@ref88]\] It has been shown that the transfusion requirements based on TEG are different in comparison to standard coagulation tests and when treated, on the basis of TEG, postoperative bleeding decreases.\[[@ref87]\] ROTEM in the post-CPB period predicts bleeding in children undergoing corrective biventricular or palliative univentricular repairs.\[[@ref88]\] One study of 107 children, however, concluded that TEG is not superior to conventional coagulation tests in predicting postoperative bleeding in children undergoing cardiac surgery and should not be used as a predictor of blood loss.\[[@ref89]\] Sonoclot as a predictor for postoperative bleeding has not been evaluated in children. The baseline parameters in cyanotic and acyanotic children have been studied, but they have not been correlated with bleeding.\[[@ref90]\] In adults, Sonoclot has been shown to predict abnormal postoperative bleeding with or without heparin neutralization.\[[@ref91][@ref92]\]

**Qualitative platelet function tests (platelet function analyzer)**

The platelet function analyzer measures the closure time when blood is passed through a small hole in a collagen membrane. A prolonged closure time indicates platelet dysfunction. A prolonged closure time in the preoperative period is associated with increased transfusion of pRBCs and fresh frozen plasma in the intraoperative period, in children undergoing cardiac surgery.\[[@ref93]\]

### Transfusion algorithm {#sec3-9}

![](ACA-19-705-g002.jpg)

To prevent dilutional coagulopathy, it is recommended to transfuse pRBC with plasma in a ratio of 1:1. Prophylactic platelet transfusion after pediatric cardiac surgery is of questionable benefit.

**Transfusion trigger**

Wypij *et al*. in 2008 published the combined results of two National Institute of Health supported trials a goal hematocrit of 30 or 35% could be achieved during CPB without greater need for transfusion.\[[@ref94]\] The authors also concluded that a hematocrit of more than 24 during CPB correlated with better psychomotor development at 1 year age. Willems *et al*. studied 125 postcardiac surgery children by allocating them into two groups on the basis of transfusion thresholds -- a restrictive group with a transfusion trigger of \<7.0 g/dl and a liberal group with a trigger of \<9.5 g/dl.\[[@ref95]\] There was no difference in the onset or progression of the multiple organ-dysfunction syndrome (MODS) in the two groups. A recent study by de Gast-Bakker *et al*. found no difference in outcomes between groups with restrictive (\<8 g/dl) and liberal (\<10.8 g/dl) thresholds. The length of hospital stay and cost of treatment was less in the restricted group.\[[@ref12]\] Children with congenital heart disease and single ventricle physiology who undergo cavopulmonary anastomosis also do not benefit from a liberal (\>13 g/dl vs. 9 g/dl) transfusion strategy.\[[@ref96]\] A North American Multicenter study of 175 children who underwent cardiac surgery revealed that 79% of patients received at least one RBC transfusion in the ICU and that only in 17% of patients the primary indication for transfusion was low hemoglobin level.\[[@ref97]\] The authors concluded that there is great variability in the transfusion practices across postcardiac surgery pediatric ICUs of North America and clear guidelines are required in this respect.

In view of many publications that have addressed the issue of blood transfusion in children following points may be considered:

There is no uniform cutoff value to define restrictive (7--9 g/dl) and liberal (9.5--13) transfusion practicesIt seems logical to have higher hematocrits in children with cyanosis and/or single ventricle physiology, in comparison to acyanotic children, but the benefits remain to be provenRestrictive transfusion strategy is safe under strict monitoring of end organ oxygenation parametersLiberal transfusion strategy is not associated with an increase in MODS or life-threatening complicationsA goal hematocrit of 30--35% should be achieved by blood conservation rather than transfusion, wherever possibleIn children with hemodynamic instability restrictive strategy is of questionable value.

### Recombinant factor VIIa {#sec3-10}

Postaprotinin era saw the emergence of rFVIIa as a rescue hemostatic agent in the postoperative patients when the bleeding appeared life threatening. Although not approved by FDA for control of postsurgery bleeding it has been used after obstetric and cardiac surgery to control refractory hemorrhage.\[[@ref98][@ref99][@ref100][@ref101][@ref102][@ref103]\] In addition to its, therapeutic role rFVIIa has also been used as a prophylactic agent to prevent excessive blood loss.\[[@ref104]\] Before administering rFVIIa, the platelet count should be fair (50,000/µl) and any consumption coagulopathy should be ruled out. Recombinant factor VIIa is contraindicated in disseminated intravascular coagulation (DIC). In DIC, there is a widespread expression of tissue factor (TF) and rFVIIa by activating this TF may cause widespread coagulation leading to death. Two major deterrents to use rFVIIa are cost and thrombosis. Due to the risk of thrombosis, the routine use of rFVIIa cannot be recommended to control postoperative bleeding after pediatric cardiac surgery. In children, a dose of 72--87 μg/kg reduces chest tube drainage and transfusion of blood and blood products. It may be beneficial to administer a second dose if there is no or suboptimal effect after the first dose.\[[@ref102]\]

### Reducing blood sampling and flushing in the postoperative period {#sec3-11}

Infants and neonates, in comparison to older children and adults, have small circulating blood volume and therefore repeated blood sampling for investigations causes loss of significant amount of blood volume. Flushing of the monitoring lines with heparinized saline also causes hemodilution. A reduction in a total number of tests done per patient not only decreases the incidence of transfusion in the postoperative period but also decreases the cost of treatment.\[[@ref105]\]

CONCLUSION {#sec1-12}
==========

Blood conservation is possible in children undergoing cardiac surgery with better outcomes. Various modalities available should be used in conjunction with one another to achieve maximum benefit. However, the risk-benefit of blood conservation should be weighed on an individual basis before practicing routinely.
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